Journal Mobile Options
Table of Contents
Vol. 79, No. 3-4, 2010
Issue release date: March 2011

Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer

Manzoni M. · Rovati B. · Ronzoni M. · Loupakis F. · Mariucci S. · Ricci V. · Gattoni E. · Salvatore L. · Tinelli C. · Villa E. · Danova M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: The efficacy of bevacizumab in metastatic colorectal cancer (mCRC) could be related not only to its well-known antiangiogenetic properties but also to a hypothetical effect on the immune system of the host. Methods: We enrolled mCRC patients treated with a bevacizumab-based first-line therapy. Lymphocyte and dendritic cell subsets were evaluated at baseline, 3rd and 6th cycle. The clinical efficacy was estimated as response rate and progression-free survival. Forty healthy subjects were used as reference. Results: Fifty-one patients were enrolled. In comparison with healthy subjects, they showed a decrease of T and B cell compartments. Bevacizumab ameliorated the impairment of lymphocyte subsets, especially for T cells. Responders showed a trend toward an increase of CD3 (p = 0.07) and CD4 (p = 0.05). Among patients with a progression-free survival >1 year, only CD19 (p = 0.033) and CD20 (p = 0.013) showed a significant increase. No baseline impairment and no significant modification of dendritic cells were found. Conclusion: Bevacizumab-based therapy is able to increase B and T cell compartments. The expansion of T lymphocytes could imply an amelioration of dendritic cell-presenting capacity. These effects correlate with a more favourable clinical outcome and could be taken into account in clinical protocols aimed at combining antiangiogenetic-therapy with immunotherapy in mCRC.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;407:249–257.
  2. Veikkola T, Karkkainem M, Claesson-Welsh L: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000;64:1130–1139.
  3. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;305:2335–2342.

    External Resources

  4. Kabbinavar F, Hambleton J, Mass RD, et al: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706–3712.
  5. Welch S, Spithoff K, Rumble RB, et al: Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 2010;21:1152–1162.
  6. Almand B, Resser JR, Lindman SN, et al: Clinical significance of defective dendritic cell differentation in cancer. Clin Canc Res 2000;6:1755–1766.
  7. Ohm JE, Carbone DP: Immune disfunction in cancer patients. Oncology 2002;16:11–18.

    External Resources

  8. Sozzani S, Rusnati M, Riboldi E, et al: Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 2007;28:385–392.
  9. Dikov MM, Ohm JE, Ray N, et al: Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 2005;174:215–222.
  10. Oyama T, Ran S, Ishida T, et al: Vascular endothelial growth factor affects dendritic cell maturation through inhibition of nuclear factor-ĸB activation in hematopoietic progenitor cells. J Immunol 1998;160:1224–1232.
  11. Ohm JE, Shurin MR, Esche C, et al: Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999;163:3260–3268.
  12. Ohm JE, Carbone P: VEGF as a mediator of tumor-associated immunodeficiency. Immun Res 2001;23:263–272.
  13. Laxmann S, Robertson SW, Wang E, et al: Vascular endothelial growth factor impairs the functional ability of dendritic cells though Id pathways. Biochem Biophys Res Commun 2005;334:193–198.
  14. Mimura K, Kono K, Kawaguchi Y, et al: Vascular endothelial growth factor inhibits the function of human mature dendritic cell mediated by VEGF receptor-2. Cancer Immunol Immunother 2007;56:761–770.
  15. Gabrilovich DI, Chen HL, Girgis KR, et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Mature Med 1996;2:1096–1103.
  16. Gabrilovich D, Ishida T, Oyama T, et al: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic linages in vivo. Blood 1998;92:4150–4166.
  17. Ohm JE, Gabrilovich DI, Sempowski GD, et al: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 2003;101:4878–4886.
  18. Gabrilovich D, Ishida T, Nadaf S, et al: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Can Res 1999;5:2963–2970.
  19. Johnson B, Osada T, Clay T, et al: Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppresion. Curr Mol Med 2009;9:702–707.
  20. Li B, Lalani AS, Harding TC, et al: Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006;12:6808–6816.
  21. Alfaro C, Suazer N, Gonzales A, et al: Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009;10:1111–1119.

    External Resources

  22. Fricke I, Mirza N, Dupont J, et al: Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007;13:4840–4848.
  23. Osada T, Chong G, Tansik R, et al: The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57:1115–1124.
  24. Rovati B, Mariucci S, Manzoni M, et al: Flow cytometric detection of circulating dendritic cells in healthy subjects. European J Hist 2008;52:45–52.
  25. Gottfried E, Kreuzt M, Mackensen A: Tumor-induced modulation of dendritic cell function. Cytokine e Growth Factors Reviews 2008;19:65–77.
  26. Gabrilovich D, Corak J, Ciernik IF, et al: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;72:483–490.
  27. Della Porta M, Danova M, Rigoli GM, et al: Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005;68:276–284.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50